LLY ELI LILLY & Co

NYSE lilly.com


$ 779.44 $ 0.00 (0 %)    

Friday, 17-Oct-2025 04:26:43 EDT
QQQ $ 591.69 $ 0.00 (0 %)
DIA $ 455.11 $ 0.00 (0 %)
SPY $ 652.75 $ 0.00 (0 %)
TLT $ 91.50 $ 0.00 (0 %)
GLD $ 399.76 $ 0.00 (0 %)
$ 819.38
$ 825.07
$ 779.42 x 1
$ 779.62 x 7
-- - --
$ 622.41 - $ 931.66
2,272,909
na
737.28B
$ 0.60
$ 53.43
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-19-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 04-30-2024 03-31-2024 10-Q
7 02-21-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 04-27-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 11-01-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 04-29-2022 03-31-2022 10-Q
15 02-23-2022 12-31-2021 10-K
16 10-27-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 04-30-2021 03-31-2021 10-Q
19 02-17-2021 12-31-2020 10-K
20 10-28-2020 09-30-2020 10-Q
21 07-31-2020 06-30-2020 10-Q
22 05-01-2020 03-31-2020 10-Q
23 02-19-2020 12-31-2019 10-K
24 10-25-2019 09-30-2019 10-Q
25 08-02-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-19-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 07-25-2018 06-30-2018 10-Q
30 04-27-2018 03-31-2018 10-Q
31 02-20-2018 12-31-2017 10-K
32 10-27-2017 09-30-2017 10-Q
33 07-28-2017 06-30-2017 10-Q
34 05-01-2017 03-31-2017 10-Q
35 02-21-2017 12-31-2016 10-K
36 10-28-2016 09-30-2016 10-Q
37 07-28-2016 06-30-2016 10-Q
38 04-29-2016 03-31-2016 10-Q
39 02-19-2016 12-31-2015 10-K
40 10-30-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 eli-lilly-novo-nordisk-hims--hers-health-shares-move-lower-after-trump-calls-out-fat-loss-drugs

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-lo...

Core News & Articles

https://www.youtube.com/watch?v=xagrobF4q1k 

 guggenheim-reiterates-buy-on-eli-lilly-maintains-948-price-target

Guggenheim analyst Seamus Fernandez reiterates Eli Lilly (NYSE:LLY) with a Buy and maintains $948 price target.

Core News & Articles

Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 ...

 eli-lillys-orforglipron-meets-all-endpoints-in-achieve-2-and-achieve-5-phase-3-trials-demonstrates-significant-a1c-reduction-and-weight-loss-in-type-2-diabetes

In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpointIn ACHIEV...

 eli-lilly-to-support-whos-international-dementia-action-plan-under-signed-collaboration

BERLIN, Oct. 13, 2025 /PRNewswire/ -- The WHO Foundation and Lilly have announced a collaboration to financially support the ai...

 eli-lilly-to-present-new-data-across-oncology-portfolio-at-esmo-2025-highlighting-verzenio-and-emerging-cancer-therapies

Eli Lilly and Company (NYSE:LLY) today announced that new data from across its oncology portfolio and pipeline will be presente...

 bill-gates-and-paho-push-to-make-weight-loss-drugs-accessible-in-low-income-nations

Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries.

 guggenheim-maintains-buy-on-eli-lilly-raises-price-target-to-948

Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $875 to $948.

 peter-marks-fda-vaccine-regulator-ousted-by-rfk-jr-joins-eli-lilly-marks-will-lead-molecule-discovery-and-infectious-diseases---stat-news

https://www.statnews.com/2025/10/07/peter-marks-former-fda-vaccine-official-joins-eli-lilly/

 long-term-study-shows-sustained-remission-with-eli-lillys-ulcerative-colitis-drug

Eli Lilly's four-year LUCENT-3 study shows Omvoh maintained high remission rates and a consistent safety profile in ulcerat...

 eli-lillys-new-data-showed-omvoh-mirikizumab-mrkz-achieves-sustained-long-term-outcomes-through-four-years-in-ulcerative-colitis-patients

Approximately 80% of Omvoh-treated patients in the LUCENT-3 study who achieved clinical remission at one year maintained long-t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION